+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Results of sub-analysis of a phase 2 study on trabectedin treatment for extraskeletal myxoid chondrosarcoma and mesenchymal chondrosarcoma



Results of sub-analysis of a phase 2 study on trabectedin treatment for extraskeletal myxoid chondrosarcoma and mesenchymal chondrosarcoma



Bmc Cancer 16: 479



Trabectedin is reported to be particularly effective against translocation-related sarcoma. Recently, a randomized phase 2 study in patients with translocation-related sarcomas unresponsive or intolerable to standard chemotherapy was conducted, which showed clinical benefit of trabectedin compared with best supportive care (BSC). Extraskeletal myxoid chondrosarcoma (EMCS) and Mesenchymal chondrosarcoma (MCS) are very rare malignant soft tissue sarcomas, and are associated with translocations resulting in fusion genes. In addition, the previous in vivo data showed that trabectedin affect tumor necrosis and reduction in vascularization in a xenograft model of a human high-grade chondrosarcoma. The aim of the present analysis was to clarify the efficacy of trabectedin for EMCS and MCS subjects in the randomized phase 2 study. Five subjects with EMCS and MCS received trabectedin treatment in the randomized phase 2 study. Three MCS subjects were allocated to the BSC group. Objective response and progression-free survival (PFS) were assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 by central radiology imaging review. The median follow-up time of the randomized phase 2 study was 22.7 months, and one subject with MCS was still receiving trabectedin treatment at the final data cutoff. The median PFS was 12.5 months (95 % CI: 7.4-not reached) in the trabectedin group, while 1.0 months (95 % CI: 0.3-1.0 months) in MCS subjects of the BSC group. The six-month progression-free rate was 100 % in the trabectedin group. One subject with MCS showed partial response, and the others in the trabectedin group showed stable disease. Overall survival of EMCS and MCS subjects was 26.4 months (range, 10.4-26.4 months) in the trabectedin group. At the final data cutoff, two of five subjects were still alive. This sub-analysis shows that trabectedin is effective for patients with EMCS and MCS compared with BSC. The efficacy results were better than previously reported data of TRS. These facts suggest that trabectedin become an important choice of treatment for patients with advanced EMCS or MCS who failed or were intolerable to standard chemotherapy. The randomized phase 2 study is registered with the Japan Pharmaceutical Information Center, number JapicCTI-121850 (May 31, 2012).

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 058761470

Download citation: RISBibTeXText

PMID: 27418251

DOI: 10.1186/s12885-016-2511-y


Related references

Cellular variant of extraskeletal myxoid chondrosarcoma of abdominal wall a case report with comparative immunohistochemical study on cartilaginous collagenous protein in various myxoid mesenchymal tumors. Journal of Cancer Research & Clinical Oncology 118(2): 147-151, 1992

Cellular variant of extraskeletal myxoid chondrosarcoma of abdominal wall a case report with comparative immunohistochemical study on cartilaginous collagenous proteins in various myxoid mesenchymal tumors. Journal of Cancer Research and Clinical Oncology 118(2): 147-151, 1992

A comparative ultrastructural study of mesenchymal chondrosarcoma and myxoid chondrosarcoma. Cancer 33(6): 1531-1542, 1974

Extraskeletal myxoid chondrosarcoma. An analysis of 34 cases. Human Pathology 3(3): 421-435, 1972

Extraskeletal myxoid chondrosarcoma: a clinicopathologic analysis of seven cases. Zhonghua Bing Li Xue Za Zhi 45(1): 25-30, 2016

Clinicopathological features of extraskeletal myxoid chondrosarcoma: An analysis of 9 cases. Chinese Journal of Cancer Research 20(3): 230-236, 2008

Extraskeletal myxoid chondrosarcoma: a clinicopathologic, immunohistochemical, and ploidy analysis of 23 cases. Modern Pathology 13(8): 900-908, 2000

Extraskeletal myxoid chondrosarcoma: a clinicopathologic, immunohistochemical, and molecular analysis of 18 cases. Human Pathology 32(10): 1116-1124, 2001

Spectrum of cytomorphological features, including literature review, of an extraskeletal myxoid chondrosarcoma with t(9;22)(q22;q12) (TEC/EWS) results in one case. Diagnostic Cytopathology 36(12): 868-875, 2008

Primary pulmonary myxoid sarcoma, a potential mimic of metastatic extraskeletal myxoid chondrosarcoma. Pathology 49(7): 792-794, 2017

Poorly differentiated extraskeletal myxoid chondrosarcoma with t(9;22)(q22;q11) translocation presenting initially as a solid variant devoid of myxoid areas. International Journal of Surgical Pathology 11(2): 137-141, 2003

Poorly Differentiated Extraskeletal Myxoid Chondrosarcoma with t(9;22) (q22;ql) Translocation Presenting Initially as a Solid Variant Devoid of Myxoid Areas. International Journal of Surgical Pathology 11(2): 137-141, 2003

Molecular analysis of the fusion of EWS to an orphan nuclear receptor gene in extraskeletal myxoid chondrosarcoma. American Journal of Pathology 150(3): 1049-1058, 1997

Metastases to the liver from extraskeletal myxoid chondrosarcoma and successful treatment with percutaneous ethanol injection. Clinical Radiology 55(4): 314-317, 2000

Intraluminal EWSR1-CREB1 gene rearranged, low-grade myxoid sarcoma of the pulmonary artery resembling extraskeletal myxoid chondrosarcoma (EMC). Histopathology 2018, 2018